彭布罗利珠单抗
医学
肿瘤科
内科学
药品
生物标志物
癌症
药物反应
药理学
遗传学
生物
免疫疗法
作者
Birgit S. Geurts,Laurien J. Zeverijn,Lindsay V.M. Leek,Jade M. van Berge Henegouwen,Louisa R. Hoes,Hanneke van der Wijngaart,Vincent van der Noort,Joris van de Haar,Annemiek van Ommen-Nijhof,Marleen Kok,Paul Roepman,Anne M.L. Jansen,Wendy W.J. de Leng,Maja J.A. de Jonge,Ann Hoeben,Carla M.L. van Herpen,Hans M. Westgeest,Lodewyk F.A. Wessels,Henk M.W. Verheul,Hans Gelderblom,Emile E. Voest
标识
DOI：10.1158/1078-0432.ccr-24-0011
摘要
To evaluate the efficacy of pembrolizumab across multiple cancer types harboring different levels of whole-genome sequencing-based tumor mutational load (TML; total of nonsynonymous mutations across the genome) in patients included in the Drug Rediscovery Protocol (NCT02925234).
科研通智能强力驱动
Strongly Powered by AbleSci AI
pluto
cdercder
昏睡的蟠桃
qiao
Oracle
bc
不倦
HEIKU
笨笨芯
iNk
平常的毛豆
小飞飞
研友_Y59785
HEAUBOOK
科研小民工
wy.he
归尘
pcr163
冰魂
善良的剑通
皖公网安备34019202002308
